芪苈强心减轻阿霉素诱导的小鼠心脏损伤

武晓栋, 姜惠敏, 姚文明, 高蓉蓉, 李新立

doi:10.12066/j.issn.1007-2861.2015

上海大学学报(自然科学版) >

2018 , Vol. 24 >Issue 2: 192 - 197

DOI: https://doi.org/10.12066/j.issn.1007-2861.2015

精准与转化医学

芪苈强心减轻阿霉素诱导的小鼠心脏损伤

展开

1. 南京医科大学第一附属医院心脏内科, 南京 210029
2. 首都医科大学附属北京中医医院检验科, 北京 100010

收稿日期: 2018-03-07

网络出版日期: 2018-05-07

基金资助

国家自然科学基金青年基金资助项目(81503283);国家自然科学基金重点资助项目(81730106)

收起

Qiliqiangxin attenuates doxorubicin induced cardiac dysfunction in mice

Expand

1. Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2. Clinical Laboratory Center, Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China

Received date: 2018-03-07

Online published: 2018-05-07

Fold

摘要

探讨了芪苈强心(Qiliqiangxin, QLQX)对阿霉素(doxorubicin, DOX)诱导的小鼠心功能下降的治疗作用. 选取 7~9 周雄性小鼠为实验对象, 将其随机分组, 通过每周腹腔注射一次阿霉素(4 mg/kg)构建小鼠心脏损伤模型, 治疗组同时口饲芪苈强心(0.5 g/(kg$\cdot$d)). 实验终点进行心脏超声检查. 实验结果表明, 芪苈强心可以减轻阿霉素诱导的心脏损伤, 保护小鼠心功能. 这提示芪苈强心有可能作为一种缓解阿霉素所致心脏损伤的药物.

关键词： 芪苈强心; 阿霉素; 心脏毒性; 线粒体

本文引用格式

武晓栋, 姜惠敏, 姚文明, 高蓉蓉, 李新立 . 芪苈强心减轻阿霉素诱导的小鼠心脏损伤[J]. 上海大学学报(自然科学版), 2018 , 24(2) : 192 -197 . DOI: 10.12066/j.issn.1007-2861.2015

Abstract

To investigate the therapeutic effects of Qiliqiangxin (QLQX) in doxorubicin (DOX)-induced cardiac dysfunction in vivo. Male mice aged 7~9 weeks were randomly divided into several groups. DOX (4 mg/kg) was injected to induce cardiotoxicity via intraperitoneal administration weekly, and QLQX was given by gavage every day for 4 weeks at a dose of 0.5 g/(kg$\cdot$d). After 4 weeks, echocardiography was performed to detect the cardiac function and it was showed that cardiac function could be significantly improved in mice treated with QLQX versus the saline. These findings indicated that QLQX could function as an intervening treatment for the patients who were treated with DOX.

Key words： Qiliqiangxin (QLQX); doxorubicin (DOX); cardiotoxicity; mitochondria

参考文献

[1]	Carvalho F S, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy[J]. Medicinal Research Reviews, 2014,34:106-135.
[2]	Arif I S, Hooper C L, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARgamma-ligands and by exploiting circadian rhythms[J]. British Journal of Pharmacology, 2013,169:1178-1188.
[3]	Zhao L, Qi Y, Xu L, et al. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting nrf2 and sirt2[J]. Redox Biology, 2018,15:284-296.
[4]	Li S, Wang W, Niu T, et al. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction[J]. Oxid Med Cell Longev, 2014,2014:748524.
[5]	Steinherz L J, Steinherz P G, Tan C, et al. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients[J]. Pediatric Blood & Cancer, 1995,24(6):352.
[6]	Cappetta D, De Angelis A, Sapio L, et al. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity[J]. Oxid Med Cell Longev, 2017(16):1521020.
[7]	Fernandez-Chas M, Curtis M J, Niederer S A. Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model[J]. British Journal of Pharmacology, 2017, DOI: 10.1111/bph.14104.
[8]	Li M S V, De Santis M C, Cimino J, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, DOI: 10.1161/CIRCULATIONAHA.117.030352.
[9]	Yuan Y P, Ma Z G, Zhang X, et al. Ctrp3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of sirt1[J]. Journal of Molecular and Cellular Cardiology, 2018,114:38-47.
[10]	Tony H, Yu K, Qiu T Z. MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction[J]. Oxid Med Cell Longev, 2015(17):597032.
[11]	Tao L, Shen S, Fu S, et al. Traditional Chinese medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice[J]. Scientific Reports, 2015, DOI: 10.1038/srep08374.
[12]	Lin S, Wu X, Tao L, et al. The metabolic effects of traditional Chinese medication Qiliqiangxin on h9c2 cardiomyocytes[J]. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 2015,37:2246-2256.
[13]	Zhang J, Wei C, Wang H, et al. Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evidence-Based Complementary and Alternative Medicine, 2013,2013:378298.
[14]	Yarana C, Carroll D, Chen J, et al. Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury[J]. Clinical Cancer Research, 2017, DOI: 10.1158/1078-0432.CCR-17-2046.
[15]	Khiati S, Dalla Rosa I, Sourbier C, et al. Mitochondrial topoisomerase 1 (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity[J]. Clinical Cancer Research, 2014,20:4873-4881.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献